scorecardresearchGlenmark Pharmaceuticals Share Price Live NSE, BSE, Today - Glenmark Pharmaceuticals

Glenmark Pharmaceuticals

BSE: 532296 | NSE: GLENMARK | ISIN: INE935A01035 | SECTOR: Biotechnology & Drugs

921.15 -7.75 (-0.83%)

04 Mar 2024, 09:59 (IST)
  • Open

    928.50
  • High

    945.75
  • Low

    919.45
  • Prev Close

    928.90
  • P/E

    -
  • Median P/E

    -
  • P/B

    -
  • Median P/B

    -
  • Market Cap

    259.94B
  • Volume

    43.46K
  • Vol. (20 day Avg.)

    0
  • PEG

    -
  • Div.Yield

    -
  • Bid

    921.50
  • Ask

    -

Company Description

  • Biotechnology & Drugs
  • BSE

    532296
  • NSE

    GLENMARK
  • ISIN

    INE935A01035

Glenmark Pharmaceuticals Limited is an India-based global pharmaceutical company. The Company is focused on building a global formulation business with branded, generics and over the counter (OTC) segments in the therapy areas of dermatology, respiratory and oncology. The Company also has a regional/country-specific presence in other therapeutic areas like diabetes, cardiovascular and oral contraceptives. Its product portfolio includes topical products, liquids, respiratory MDI/DPI, complex injectables and biologics, and oral solids. The Company has a bioequivalent version of Tiotropium Bromide dry powder inhaler (DPI) under the brand, Tiogiva in the United Kingdom and Tavulus in Spain, for the treatment of chronic obstructive pulmonary disease. Ryaltris, the Company's first branded specialty product globally, is a fixed dose combination nasal spray that combines an antihistamine (Olopatadine) with a steroid (Mometasone Furoate) for treatment of allergic rhinitis.

Company Officers

  • Glenn Saldanha

    Executive Chairman of the Board, Managing Director
  • V. S. Mani

    Global Chief Financial Officer, Executive Director
  • Harish Kuber

    Compliance Officer, Company Secretary
  • Cherylann Pinto

    Executive Director - Corporate Services